The US Food and Drug Administration has approved a supplemental new drug application (sNDA) for an abuse-deterrent, extended-release oxycodone formula (Xtampza, Collegium Pharmaceutical) for the management of severe pain that requires daily, long-term opioid treatment.
The approval resulted in 3 main changes to the label. Pharmacokinetic, comparative data for the extended-release drug will be added, showing a comparison with the abuse-deterrent version (more…)
Emergency department visits alone rose 100 percent between 2005 and 2014 Ken Serrano
Notoriously potent synthetic opioids manufactured into pill form that resembled the appearance of another painkiller were found in Monmouth County for the first time, according to the county prosecutor’s office.
The carfentanil and cyclopropyl fentanyl pills, which resemble the appearance (more…)